Nct00074971 fabrazyme?

What is NCT00074971 (Fabrazyme)?

NCT00074971 is a ClinicalTrials.gov identifier for a Fabrazyme (agalsidase beta) study in Fabry disease. The trial is listed under the drug name Fabrazyme (agalsidase beta) on ClinicalTrials.gov.

Which company makes Fabrazyme (agalsidase beta)?

Fabrazyme (agalsidase beta) is marketed by Sanofi.

What is Fabrazyme used for in Fabry disease?

Fabrazyme is used to treat Fabry disease, a lysosomal storage disorder caused by deficient activity of the enzyme alpha-galactosidase A.

How does Fabrazyme work?

Fabrazyme provides an engineered form of the missing enzyme (agalsidase beta), which helps break down globotriaosylceramide (Gb3) that accumulates in tissues in Fabry disease.

Where can I read the official trial details for NCT00074971?

Search for “NCT00074971” on ClinicalTrials.gov to see the study design, endpoints, enrollment, locations, and results status for that specific Fabrazyme trial.

Are there patents or exclusivity details tied to Fabrazyme?

DrugPatentWatch.com tracks patent and exclusivity information for branded drugs like Fabrazyme and can help you find relevant patent filings and expiry timelines. You can look up Fabrazyme on DrugPatentWatch here: https://www.drugpatentwatch.com/

Sources

1. https://clinicaltrials.gov/ (search: NCT00074971)
   
2. https://www.drugpatentwatch.com/ (search: Fabrazyme)